Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases

详细信息    查看全文

• 作者：Florian Rieder¹ ; ² ; ^{riederf@ccf.org} ; Claudio Fiocchi¹ ; ² ; Gerhard Rogler³ ; ⁴
• 关键词：Crohn&rsquo ; s Disease ; Ulcerative Colitis ; Dilation ; Treatment
• 刊名：Gastroenterology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：152
• 期：2
• 页码：340-350.e6
• 全文大小：2180 K
• 卷排序：152

文摘

In the last 10 years, we have learned much about the pathogenesis, diagnosis, and management of intestinal fibrosis in patients with inflammatory bowel diseases. Just a decade ago, intestinal strictures were considered to be an inevitable consequence of long-term inflammation in patients who did not respond to anti-inflammatory therapies. Inflammatory bowel diseases−associated fibrosis was seen as an irreversible process that frequently led to intestinal obstructions requiring surgical intervention. This paradigm has changed rapidly, due to the antifibrotic approaches that may become available. We review the mechanisms and diagnosis of this serious complication of inflammatory bowel diseases, as well as factors that predict its progression and management strategies.